Genesis Pharmaceuticals Enterprises

Jiangbo Pharmaceuticals, Inc. (formerly Genesis Pharmaceuticals Enterprises, Inc.) was a pharmaceutical company primarily operating in China, specializing in the research, development, and manufacturing of Western and Traditional Chinese Medicines (TCM). The company's product portfolio included various formulations such as tablets, capsules, and granules, with key products like Clarithromycin and Felodipine sustained-release tablets. After a period of expansion and the acquisition of Hongrui Pharmaceuticals, the company faced significant regulatory scrutiny and was delisted from NASDAQ in 2011 due to financial reporting failures. It is currently inactive as a public entity following SEC enforcement actions.